Measure the Disease, Not Just the Marker In part 1 of this series, we discussed how two separate clinical trials reduced cardiovascular-associated biomarkers but didn’t reduce cardiovascular events or death in the trial populations [1, 2]. While speculation abounds over the perceived “failure” of these trials, the important underlying question often gets missed or unanswered: …
We are proud to announce that CSI has partnered with Innovation Factory (iF) as a resource partner, extending our expert writing and strategic communications services to the accelerator’s growing community of life sciences, biotech, and medical device startups. Innovation Factory is one of Southern Ontario’s leading business accelerators, having supported more than 4,000 Ontario businesses …
When the Biomarker Moves but the Patient Doesn’t Sometimes a drug does exactly what it was designed to do and still fails. That uncomfortable reality has played out dramatically over the past several weeks. On September 4, Novartis announced that pelacarsen, an investigational antisense oligonucleotide targeting lipoprotein(a), or Lp(a), had failed to reduce cardiovascular events …